KVLE yields 8.98% · PFE yields 6.13%● Live data
📍 PFE pulled ahead of the other in Year 10
Combined, KVLE + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of KVLE + PFE for your $10,000?
KVLE is passively managed to provide exposure to US companies that have high dividend yields that rank well on Value Lines proprietary system for safety and timeliness. The Value Line Safety Ranking System measures risk based on price stability and financial strength, while the Timeliness Ranking System measures price performance over a period. From the ranked companies, stocks are narrowed down by selecting those with the best dividend and beta target. Companies with 25% of the highest dividend-yielding stocks and those with a beta target of between 0.8 to 1 are selected. Finally, each company is assigned a score based on their Safety and Timelines rank, which determines their weighting. This approach allows the fund to adapt to the market environment. The index is rebalanced monthly. Before September 29, 2023, the fund traded as KFA Value Line Dynamic Core Equity Index ETF and prior to January 4, 2024, its index was 3D/L Value Line Dynamic Core Equity Index.
Full KVLE Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.